Factor Xa
Concept
Vocabulary Service
Overview
subject area of
-
4 Clinical potential of low molecular weight heparins Academic Article
-
A Control Switch for Prothrombinase Academic Article
-
A PoTENtial Antidote Academic Article
-
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers Academic Article
-
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer Academic Article
-
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin Academic Article
-
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial Academic Article
-
Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and d-Phe-Pro-Arg-Ch2Cl Academic Article
-
Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin Academic Article
-
Age-related differences in heparin response Academic Article
-
An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice Conference Paper
-
An overview of clinical trials of low molecular weight heparin fractions. Academic Article
-
An overview of the mechanism of action of antithrombin and its inherited deficiency states Academic Article
-
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors Academic Article
-
Andexanet Alfa for Bleeding with Factor Xa Inhibitors Academic Article
-
Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban Academic Article
-
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity Academic Article
-
Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence Academic Article
-
Andexanet alfa for the treatment of hemorrhage Academic Article
-
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis Academic Article
-
Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa Academic Article
-
Bleeding Complications and Management on anticoagulant therapy Academic Article
-
Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin Academic Article
-
Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity Academic Article
-
Chemical–Physical Characterization of Polyurethane Catheters Modified with a Novel Antithrombin-Heparin Covalent Complex Academic Article
-
Clinical implications of reversal agents for direct oral anticoagulants Academic Article
-
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist Academic Article
-
Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins Academic Article
-
Covalent antithrombin–heparin complexes Academic Article
-
Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets Academic Article
-
Dabigatran: ready for prime time? Academic Article
-
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation Academic Article
-
Duration of anticoagulant therapy for venous thromboembolism Academic Article
-
Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo Academic Article
-
Effects of Sulfated Polysaccharides on Inhibition of Thrombus Formation initiated by Different Stimuli Academic Article
-
Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III Academic Article
-
Enoxaparin Use in the Neonatal Intensive Care Unit: Experience Over 8 Years Academic Article
-
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. Academic Article
-
Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding Academic Article
-
Factor Xa or thrombin: Is thrombin a better target? Conference Paper
-
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors Academic Article
-
Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits Academic Article
-
Glycosaminoglycans Bind Factor Xa in a Ca2+-Dependent Fashion and Modulate Its Catalytic Activity Academic Article
-
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care Academic Article
-
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy Academic Article
-
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Academic Article
-
Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance Academic Article
-
Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate Academic Article
-
Heparin and Low Molecular Weight Heparins Inhibit Prothrombinase Formation but not its Activity in Plasma Academic Article
-
Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases Academic Article
-
Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma Academic Article
-
Hirudin causes more bleeding than heparin in a rabbit ear bleeding model Academic Article
-
How can we reverse bleeding in patients on direct oral anticoagulants? Academic Article
-
How to use unfractionated heparin to treat neonatal thrombosis in clinical practice Academic Article
-
Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase Academic Article
-
Immobilization of an antithrombin–heparin complex on gold: Anticoagulant properties and platelet interactions Academic Article
-
In the Presence of Phospholipids, Glycosaminoglycans Potentiate Factor Xa-Mediated Protein C Activation by Modulating Factor Xa Activity Academic Article
-
In vivo Effects of Low Molecular Weight Heparins on Experimental Thrombosis and Bleeding Academic Article
-
Incorporation of Factor Va into Prothrombinase Is Required for Coordinated Cleavage of Prothrombin by Factor Xa Academic Article
-
Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate Academic Article
-
Inhibition of Fibrin-Bound Thrombin by a Covalent Antithrombin-Heparin Complex Academic Article
-
Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082 Academic Article
-
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex Academic Article
-
Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys Academic Article
-
Letter to the editor Academic Article
-
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial Academic Article
-
Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo Academic Article
-
Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex Academic Article
-
Mechanisms responsible for the failure of protamine
to inactivate low-molecular-weight heparin Academic Article
-
Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency Academic Article
-
Monitoring and reversal of direct oral anticoagulants Academic Article
-
Monitoring the anticoagulant effect after a massive rivaroxaban overdose Academic Article
-
Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation Academic Article
-
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank Academic Article
-
Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate Academic Article
-
New Antithrombotic Drugs: Potential for Use in Oncology Academic Article
-
Novel oral anticoagulants and reversal agents: Considerations for clinical development Academic Article
-
Oral Anticoagulant Therapy Academic Article
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement Academic Article
-
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases Academic Article
-
PRE‐OPERATIVE FACTOR Xa–TFPI AND POST‐OPERATIVE VENOUS THROMBOSIS Academic Article
-
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma Academic Article
-
Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex Academic Article
-
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Academic Article
-
Rationale Behind the Development of Low Molecular Weight Heparin Derivatives Academic Article
-
Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent Academic Article
-
Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins Academic Article
-
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients Academic Article
-
Reversal agents for non-vitamin K antagonist oral anticoagulants Academic Article
-
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions Academic Article
-
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum Academic Article
-
Reversal of direct oral anticoagulants: a practical approach Academic Article
-
Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study Academic Article
-
Serum-induced platelet procoagulant activity: An assay for the characterization of prothrombotic disorders Academic Article
-
Site-directed mutagenesis of the P2 residue of human antithrombin Academic Article
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations Academic Article
-
The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study Academic Article
-
The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studiesin vitro Academic Article
-
The haemorrhagic and antithrombotic effects of dermatan sulphate. Academic Article
-
The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate Academic Article
-
The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor Academic Article
-
The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin Academic Article
-
The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase Academic Article
-
The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery Academic Article
-
The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin Academic Article
-
Thrombolysis by chemically modified coagulation factor Xa Academic Article
-
Thrombosis in inherited factor VII deficiency Academic Article
-
Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity Academic Article
-
Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa Academic Article
-
Utility of aPTT in monitoring unfractionated heparin in children Academic Article
-
Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected withStaphylococcus epidermidis: Role of monocyte procoagulant activity induced by bacterial supernatant Academic Article
-
Volutrauma activates the clotting cascade in the newborn but not adult rat Academic Article
-
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH Academic Article
-
Zn2+ Mediates High Affinity Binding of Heparin to the αC Domain of Fibrinogen Academic Article